13F Holdings
中文EN

OKUR OnKure Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1637715 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY2.5%
TTM EPS YoY-102.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-55.2%
ROA-51.6%
ROIC (approx.)-4,360.7%
Asset turnover—

Leverage & solvency

Liabilities / assets5.6%
Debt / equity0.00x
Current ratio18.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—$0———
R&D expense$48.26M$43.80M$32.12M$37.70M$28.17M
SG&A expense$14.69M$10.59M$4.82M$16.14M$11.65M
Operating income-$62.95M-$54.39M-$36.93M-$53.85M-$39.82M
Pretax income——-$77.39M-$51.95M-$39.77M
Income tax$0$0$0$0$0
Net income-$59.52M-$52.67M-$35.31M-$51.95M-$39.77M
EBITDA-$62.50M-$53.93M-$36.52M-$53.76M-$39.77M
EPS (basic)-4.40-15.28-124.41-2.12-2.19
EPS (diluted)-4.40-15.28-124.41-2.12-2.19
Weighted avg. shares (diluted)13.52M3.45M283,81724.50M18.14M
Banking
Net interest income$3.43M$1.71M$1.62M——
Balance sheet
Cash & equivalents$59.05M$110.76M$29.88M$11.54M$124.66M
Short-term investments$0—$75.33M$81.25M$23.01M
Current assets$60.84M$113.00M$33.77M$106.35M$153.73M
PP&E, net$618,000$1.02M$1.43M$453,000$212,000
Total assets$62.12M$114.91M$35.73M$108.18M$154.02M
Current liabilities$5.92M$10.53M$7.29M$7.12M$6.20M
Total liabilities$5.93M$11.08M$7.75M$8.21M$6.81M
Shareholders' equity$56.18M$103.83M-$101.84M-$54.42M$147.21M
Shares outstanding——3.34M24.70M24.46M
Cash flow statement
Operating cash flow-$51.83M-$51.12M-$34.55M-$47.36M-$37.98M
Capital expenditure$46,000$52,000$246,000$346,000$198,000
Free cash flow-$51.87M-$51.17M-$34.79M-$47.71M-$38.18M
Investing cash flow-$46,000$15.87M-$246,000-$57.84M-$23.38M
Financing cash flow$163,000$116.13M$53.12M$471,000$132.41M
Depreciation & amortization$447,000$459,000$417,000$88,000$50,000
Stock-based compensation$11.63M$4.53M$199,000$4.32M$3.89M
Share buybacks——$4.40M——

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.